Dual GLUT1/3 depletion overcomes JAK2 inhibitor resistance in myeloproliferative neoplasms
Background: Limitations of Single JAK2 Inhibitor Targeting and Metabolic Bypass Pathways in Myeloproliferative Neoplasm (MPN) Research and Development
Traditional therapeutic strategies for myeloproliferative neoplasms (MPNs) have relied on cytoreductive symptomatic therapies using selective inhibitors such as ruxolitinib or fedratinib. However, single-pathway blockade fails to eradicate the source of JAK2V617F clones and does not fully control drug resistance and microenvironment survival feedback loops. In particular, conventional static baseline transcriptomic analysis guidelines do not reflect the structural degradation noise and temporal loss of biological function that occur during single-cell dissociation, which prevents proactive control of inter-clonal heterogeneity and drug-induced compensatory flux in silico. This has led to critical predictive errors in achieving effective therapeutic concentrations in clinical settings and has remained a bottleneck in patient-specific target activation.
Discovery: Activation of CRISPR-Cas9-Mediated GLUT1/3 Compound Deficiency Model and Demonstration of Single-Cell Resolution Multi-Omics Independent Variable Tensor Synchronization
This study revealed that the JAK2V617F mutation triggers metabolic reprogramming through the activation of hypoxia-inducible factor 1 (HIF-1), leading to a significant upregulation of intracellular glucose flux. By implementing a single-cell resolution multi-omics independent variable tensor, we demonstrated that the functional compensation and replicative redundancy between glucose transporters GLUT1 (SLC2A1) and GLUT3 (SLC2A3) are critical metabolic backbones for tumor survival. In silico calculations, including the determination of glucose uptake rate constants and precise tuning of ligand binding free energy, revealed that single-target inhibition activates alternative metabolic pathways, and only combined GLUT1/3 dual-target blockade results in complete cellular starvation. Profiling analysis with batch effects computationally removed demonstrated the induction of replication stress and S-phase cell cycle arrest, leading to destructive activation of apoptosis and confirming molecular biological integrity.
Establishment of a Rate-Limiting Metabolic Pathway Modulation and Reversible Homeostatic Precision Stratification Model
Based on a multi-dimensional clinical patient cohort omics matrix, including primary myelofibrosis (PMF), this architecture established a precision stratification model based on JAK2V617F mutation activity and HIF-1 response gradients. By introducing a modulation approach that down- or up-regulates the key rate-limiting step constant of glucose uptake, we constructed a reversible homeostatic autonomous regulation backbone that selectively targets abnormal tumor cells without damaging normal cells, even under aberrant metabolic stress in the tumor microenvironment. This model is designed to flexibly respond to dynamic physiological variations in vivo, including heterologous organ and splenic hematopoietic activation, and to ensure a high-resolution safety domain that minimizes off-target toxicity of therapeutic agents.
Prospects: Establishment of a Programmable Systems Biology Standard and Implementation of a Next-Generation IND Digital Governance Framework
This high-resolution computational metabolic landscape platform goes beyond static, post-hoc therapeutic models and establishes a programmable systems biology standard based on multi-dimensional tensor data. At the high-throughput screening (HTS) stage, a genetic gradient correction engine is applied to compensate for microenvironment variations, strengthening the computational barrier by neutralizing inter-sample batch effects and zeroing out inter-batch deviations. This in silico metabolic flux prediction framework meets the requirements for next-generation companion diagnostic (CDx) co-approval and will serve as a unique digital governance master asset that quantitatively demonstrates the synergistic efficacy of new drug candidates with existing ruxolitinib, disruptively shortening the IND approval and cGMP commercial launch timelines.
BACKGROUND: Myeloproliferative neoplasms (MPN) comprise a heterogenous group of hematological malignancies that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Current therapeutic strategies rely on cytoreductive approaches that mitigate disease burden and thromboembolic risk but are not curative. Allogeneic stem cell transplantation remains the only curative option, underscoring the need for novel therapeutic strategies. We previously identified hypoxia-inducible factor 1 (HIF-1) as a selective vulnerability in JAK2V617F-positive cells, but the underlying metabolic mechanisms remain incompletely defined. METHODS: In vitro studies utilized 32D cells transduced with an empty vector control, Jak2WT, or Jak2V617F. To evaluate metabolic dependencies, CRISPR-Cas9 was used to generate Slc2a1 (GLUT1) and Slc2a3 (GLUT3) knockout clones, which were subsequently characterized via RNA sequencing, extracellular flux analysis, and cellular fitness assays (proliferation, viability, and apoptosis). Pharmacological targeted inhibition of GLUT1/3 was evaluated in human JAK2V617F-mutated post-MPN AML cell lines (SET-2, HEL), primary patient-derived cells and a Jak2V617F knock-in mouse model. Combinatorial efficacy was assessed using the JAK1/2 inhibitor ruxolitinib. RESULTS: JAK2V617F induced HIF-1-dependent metabolic reprogramming, characterized by increased glycolytic flux and oxidative metabolism. Complete abrogation of glucose uptake occurred only upon combined loss of GLUT1 and GLUT3 in Jak2V617F cells, revealing functional redundancy between these transporters that sustains enhanced glycolysis. Disruption of glucose uptake selectively induced stress-associated transcriptional programs and replication stress, triggering an S-phase arrest that culminated in apoptosis and impaired viability, specifically in Jak2V617F cells. In vivo, pharmacological inhibition of HIF-1 or GLUT induced a reorganization of erythropoiesis to the splee
The discovery of GLUT1/3 compound blockade in this study goes beyond theoretical exploration of tumor metabolism and directly translates into the global market for rare blood cancer curative drugs and the next generation of precision medicine business lines.
First, in the clinical setting, the in silico computational analysis algorithm can immediately scan for JAK2V617F mutations and GLUT1/3 compound expression rates, eliminating the temporal noise inherent in conventional pathology and maintaining a drug-responsive protective barrier against resistant cancer cells.
At the same time, by linking to an open-source dinucleotide cluster and NCBI GEO database containing patient-derived single-cell transcriptomic matrices, a companion diagnostic (CDx) panel interface can be realized that virtually simulates confounding variables in clinical trial design and real-time reverse-calculates the effective docking concentration of compound metabolic inhibitors.
Furthermore, when conducting large-scale clinical trials for next-generation myeloproliferative neoplasm therapies by multinational companies, linking the in vivo intracellular glucose inhibition and starvation induction activity values as a correction factor will zero out inter-batch cellular engraftment activity deviations and maximize the probability of obtaining regulatory approval and cGMP commercial launch permits from global regulatory agencies, functioning as a backbone infrastructure.